

43

 참고 문헌

1. 나중구, 남궁성은, 심명례. Candida성 질염에서의 Clotrimazole (Canestene)의 치료효과. 대한산부회지 1980;23:741-6.
2. 대한산부인과학회. 부인과학. 제4판. 대한산부인과학회 교과서편찬위원회. 도서출판 고려의학; 2007; 147-69.
3. 서경, 김세광, 박용원, 조재성, 최인철, 이국 등. 임신부의 질 세균증(bacterial vaginosis)가 임신 결과에 미치는 영향. 대한산부회지 1994;37:260-5.
4. 장윤석, 최영민, 김정훈. Candida성 질염 치료에서의 Itraconazole (sporonox)에 대한 임상적 평가. 대한산부회지 1990;33:153-60.
5. 최순미, 서경, 오연수, 박정식, 허경순, 이국. 가임기 여성의 질 세균증 진단에서 자궁경부 세포진 검사의 유용성. 대한산부회지 1998;41:1323-9.
6. Akinbiyi AA, Watson R, Feyi-Waboso P. Prevalence of Candida albicans and bacterial vaginosis in asymptomatic pregnant women in South Yorkshire, United Kingdom. Outcome of a prospective study. Arch Gynecol Obstet 2008;278:463-6.
7. Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006;42:8-13.
8. Aral SO, Mosher WD, Cates W Jr. Self-reported pelvic inflammatory disease in the United States, 1988. JAMA 1991;266:2570-3.
9. Beigi RH, Wiesenfeld HC. Pelvic inflammatory disease: new diagnostic criteria and treatment. Obstet Gynecol Clin North Am 2003;30:777-93.
10. Bignell C, M FitzGerald, and (Guideline Development Group) UK national guideline for the management of gonorrhoea in adults, Int J STD AIDS October 2011;22 541-7.
11. Boardman LA, Peipert JF, Brody JM, Cooper AS, Sung J. Endovaginal sonography for the diagnosis of upper genital tract infection. Obstet Gynecol 1997;90:54-7.
12. Bodsworth NJ, Crooks RJ, Borelli S, Vejlsgaard G, Paavonen J, Worm AM, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med 1997;73:110-6.
13. Bowden FJ. Donovanosis in Australia: going, going. Sex Transm Infect 2005;81:365-6.
14. Brandt M, Abels C, May T, Lohmann K, Schmidts-Winkler I, Hoyme UB. Intravaginally applied metronidazole is as effective as orally applied in the treatment of bacterial vaginosis, but exhibits significantly less side effects. Eur J Obstet Gynecol Reprod Biol 2008;141:158-62.
15. Brown ST, Zaidi A, Larsen SA, Reynolds GH. Serological response to syphilis treatment. A new analysis of old data. JAMA 1985;253:1296-9.
16. Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley RL, et al. Acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997;337:509-15.
17. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003;289:203-9.
18. Bulterys M, Weidle PJ, Abrams EJ, Fowler MG. Combination antiretroviral therapy in African nursing mothers and drug exposure in their infants: new pharmacokinetic and virologic findings. J Infect Dis 2005;192:709-12.
19. Cacciatore B, Leminen A, Ingman-Friberg S, Ylostalo P, Paavonen J. Transvaginal sonographic findings in ambulatory patients with suspected pelvic inflammatory disease. Obstet Gynecol 1992;80:912-6.
20. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, et al. Effect of aciclovir on HIV-1 acquisition in

- herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;371:2109-19.
21. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 2010;59:626-9.
 22. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males- Advisory Committee on Immunization Practice (ACIP), 2011. *MMWR Morb Mortal Wkly Rep* 2011;23:1705-8.
 23. Chosidow O, Drouault Y, Leconte-Veyriac F, Aymard M, Ortonne JP, Pouquet F, et al. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. *Br J Dermatol* 2001;144:818-24.
 24. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. *Lancet Oncol* 2005;6:204.
 25. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ. International Valaciclovir HSV Study Group. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. *Int J STD AIDS* 2002;13:12-21.
 26. Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. *Lancet* 2002;359:108-13.
 27. Das S, Huengsborg M, Shahmanesh M. Treatment failure of vaginal trichomoniasis in clinical practice. *Int J STD AIDS*. 2005;16:284-6.
 28. Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. *Ann Intern Med* 2008;148:493-500.
 29. David ES. Genitourinary infections and sexually transmitted diseases in Jonathan SB, Eli TD, aula AH, Novak' *Gynecology*. 12th ed, Baltimore Williams & Wilkins; 1996; 429.
 30. David ES. Genitourinary infections and sexually transmitted diseases in Jonathan SB, Berek & Novak's *Gynecology*. 14th ed, Baltimore Williams & Wilkins; 2007; 541-60.
 31. De Panfilis G., Melzani G, Mori G, Ghidini A, Graifemberghi S. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. *Sex Transm Dis* 2002;29:121-5.
 32. DeJesus E, Wald A, Warren T, Schacker TW, Trottier S, Shahmanesh M, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. *J Infect Dis* 2003;188:1009-16.
 33. Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. *JAMA* 1998;280:887-92.
 34. Dolev JC, Maurer T, Springer G, Glesby MJ, Minkoff H, Connell C, et al. Incidence and risk factors for verrucae in women. *AIDS* 2008;22:1213-9.
 35. Dunlop EMC. Survival of treponemes after treatment, comments, clinical conclusions and recommendations. *Genitourin Med* 1985;61:293-301.
 36. Dykers JR. Single-dose metronidazole for trichomonal vaginitis. Patient and consort. *N Engl J Med* 1975;293:23-4.
 37. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. *J Infect Dis* 2007;196:266-70.
 38. Eschenbach DA. Epidemiology and diagnosis of acute pelvic inflammatory disease. *Obstet Gynecol* 1980;55:142S-52S.
 39. Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. *Sex Transm Dis* 1997;24:481-6.
 40. Fihn SD, Latham RH, Roberts P, Running K, Stam WE. Association between diaphragm use and urinary tract infection. *JAMA* 1985;254:240-5.
 41. French P, Gomberg M, Janier M, Schmidt B, van Voorst Vader P, Young H, et al'. IUSTI: 2008 European Guidelines on the Management of Syphilis. *Int J STD AIDS* 2009;20:300-9.
 42. French P, Van Voorst Vader PC. Serologic Follow-up after Treatment for Syphilis in Europe. 2004. IUSTI/WHO Conference on STI. Europe Syphilis Guideline Expert Workshop, Mykonos, Greece Gagliardi PD, Hoffer PB, Rosenfield AT. Correlative imaging in abdominal infection: an algorithmic approach using nuclear medicine, ultrasound, and computed tomography. *Semin Nucl Med* 1988;18:320-34.
 43. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo

- arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. *J Infect Dis* 2009;199:805-14.
44. Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. *CID* 2006;42:45-9.
45. Gilbert LK, Wyand F. Genital herpes education and counseling: testing a one-page? FAQ intervention. *Herpes* 2009;15:51-6.
46. Gjelland K, Ekerhovd E, Granberg S. Transvaginal ultrasound-guided aspiration for treatment of tubo-ovarian abscess: a study of 302 cases. *Am J Obstet Gynecol* 2005;193:1323-30.
47. Golden M, Kerani R, Shafii T, Whittington W, Holmes K. Does azithromycin co-treatment enhance the efficacy of oral cephalosporins for pharyngeal gonorrhea? Presented at: 18th International Society for STD Research (ISSTD) Conference, London, UK: 2009.
48. Gotovtseva EP, Kapadia AS, Smolensky MH, Lairson DR. Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis. *Sex Transm Dis* 2008;35:346-51.
49. Grimes DA. Deaths due to sexually transmitted diseases. *JAMA* 1986;255:1727-9.
50. Gross G, Meyer KG, Pres H, Thielert C, Tawfik H, Mescheder A. A randomized, double-blind, four-arm parallel-group, placebocontrolled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. *J Eur Acad Dermatol Venereol* 2007;21:1404-12.
51. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. *JAMA* 1999;281:736-8.
52. H J C de Vries, S A Morre, J A White, H Moi. European guideline for the management of lymphogranuloma venereum, 2010. *Int J STD AIDS* 2010;21:533-6.
53. Hemila M, Henriksson L, Ylikorkala O. Serum CRP in the diagnosis and treatment of pelvic inflammatory disease. *Arch Gynecol Obstet* 1987;241:177-82.
54. Hillier SL, Kiviat NB, Hawes SE, Hasselquist MB, Hanssen PW, Eschenbach DA, et al. Role of bacterial vaginosis-associated microorganism in endometritis. *Am J Obstet Gynecol* 1996;175:435-41.
55. Holland J, Young ML, Lee O, C-A Chen S. Vulvovaginal carriage of yeasts other than *Candida albicans*. *Sex Transm Infect* 2003;79:249-50.
56. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. *J Infect Dis* 2008;198:687-3.
57. Hopkins GB, Kan M, Mende CW. Gallium-67 scintigraphy and intraabdominal sepsis: clinical experience in 140 patients with suspected intraabdominal abscess. *West J Med* 1976;125:425-30.
58. Jacobson L, Westrom L. Objectivized diagnosis of acute pelvic inflammatory disease. *Am J Obstet Gynecol* 1969;105:1088-98.
59. Jones RB. New treatments for Chlamydia trachomatis. *Am J Obstet Gynecol* 1991;164:1789-93.
60. Joseph AK, Rosen T. Laboratory techniques used in the diagnosis of chancroid, granuloma inguinale, and lymphogranuloma venereum. *Dermatol Clin* 1994;12:1-8.
61. Jossens MO, Eskenazi B, Schachter J, Sweet RL. Risk factors for pelvic inflammatory disease: a case-control study. *Sex Transm Dis* 1996;23:239-47.
62. Jossens MO, Schachter J, Sweet RL. Risk factors associated with pelvic inflammatory disease of differing microbial etiologies. *Obstet Gynecol* 1994;83:989-97.
63. Kahn JG, Walker CK, Washington AE, Landers DV, Sweet RL. Diagnosing pelvic inflammatory disease: a comprehensive analysis and considerations for developing a new model. *JAMA* 1991;266:2594-604.
64. Kemp M, Christensen JJ, Lautenschlager S, Vall-Mayans M, Moi H. European guideline for the management of chancroid, 2011. *Int J STD AIDS* 2011;22:241-4.
65. Kiviat NB, Paavonen JA, Wøolner-Hanssen P, Critchlow CW, Stamm WE, Douglas J, et al. Histopathology of endocervical infection caused by Chlamydia trachomatis, herpes simplex virus, Trichomonas vaginalis, and Neisseria gonorrhoeae. *Hum Pathol* 1990;21:831-7.
66. Koumans EH, Sternberg M, Bruce C, McQuillan G, Kendrick J, Sutton M, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004: associations with symptoms, sexual behaviors, and reproductive health. *Sex Transm Dis* 2007;34:864-9.
67. Krieger JN, Tam MR, Stevens CE, Nielsen IO, Hale J, Kiviat NB, et al. Diagnosis of trichomoniasis. Comparison of conventional wet-mount examination with cytologic studies, cultures, and monoclonal antibody staining of direct specimens. *JAMA* 1988;259:1223-7.
68. Landers DV, Sweet RL. Tubo-ovarian abscess: contemporary approach to management. *Rev Infect Dis* 1983;5:876-84.
69. Lanjouw E, Ossewaarde JM, Sary A, Boag F, van der Meijden WI. 2010 European guideline for the management of Chlamydia trachomatis infections. *Int J STD AIDS* November 2010;21:729-37.

70. Lareau SM, Beigi RH. Pelvic inflammatory disease and tubo-ovarian abscess. *Infect Dis Clin N Am* 2008;22:693-708.
71. Lehtinen M, Laine S, Heinonen PK, Teisala K, Miettinen A, Aine R, et al. Serum C-reactive protein determination in acute pelvic inflammatory disease. *Am J Obstet Gynecol* 1986;154:158-9.
72. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. *Clin Infect Dis* 2002;34:958-62.
73. Lewis DA, Young H. Testing guidelines for individual sexually transmitted infections ? syphilis. UK national screening and testing guidelines for sexually transmitted infections. *Sex Transm Infect* 2006;82:13-5.
74. Lindner JG, Plantema FH, Hoogkamp-Korstanje JA. Quantitative studies of the vaginal flora of healthy women and of obstetric and gynaecological patients. *J Med Microbiol* 1978;11:233-41.
75. Lopez-Zeno JA, Keith LG, Berger GS. The Fitz-Huge-Curtis syndrome revisited: changing perspectives after half a century. *J Reprod Med* 1985;30:567-82.
76. Luger AFH. Serological diagnosis of syphilis: current methods. In: Young H, McMillan A, eds. *Immunological Diagnosis of Sexually Transmitted Diseases*. New York: Marcel Dekker; 1988: 249-74.
77. Lyng J, Christensen J. A double-blind study of the value of treatment with a single dose tinidazole of partners to females with trichomoniasis. *Acta Obstet Gynecol Scand* 1981;60:199-201.
78. Mabey D, Peeling RW. Lymphogranuloma venereum. *Sex Transm Infect* 2002;78:90-2.
79. Mammen-Tobin A, Wilson JD. Management of metronidazole-resistant *Trichomonas vaginalis*? a new approach. *Int J STD AIDS* 2005;16:488-90.
80. Marcone V, Calzolari E, Bertini M. Effectiveness of vaginal administration of *Lactobacillus rhamnosus* following conventional metronidazole therapy: how to lower the rate of bacterial vaginosis recurrences. *New Microbiol* 2008;31:429-33.
81. Mardh PA, Lind I, Svensson L, Westrom L, Moller BR. Antibodies to *Chlamydia trachomatis*, *Mycoplasma hominis* and *Neisseria gonorrhoeae* in serum from patients with acute salpingitis. *Br J Vener dis* 1981;57:125-9.
82. Markos AR. The concordance of *Chlamydia trachomatis* genital infection between sexual partners, in the era of nucleic acid testing. *Sex Health*. 2005;2:23-4.
83. Marrazzo JM, Antonio M, Agnew K, Hillier SL. Distribution of genital *Lactobacillus* strains shared by female sex partners. *J Infect Dis* 2009;199:680-3.
84. Martin ET, Krantz E, Gottlieb SL, Magaret AS, Langenberg A, Stanberry L, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. *Arch Intern Med* 2009;169:1233-40.
85. Mashiah J, Brenner S. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. *Clin Exp Dermatol* 2008;33:74-6.
86. McClean KL, Sheehan GJ, Harding GK. Intraabdominal infection: a review. *Clin Infect Dis* 1994;19:100-16.
87. Mertz GJ, Loveless MO, Levin MJ, Kraus SJ, Fowler SL, Goade D, et al. Collaborative Famciclovir Genital Herpes Research Group. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, double-blind, placebo-controlled trial. *Arch Intern Med* 1997;157:343-49.
88. Mofenson LM. Centers for Disease Control and Prevention, U.S. Public Health Service Task Force. U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. *MMWR Recomm Rep* 2002;51:1-38.
89. Morrow R, Friedrich D. Performance of a novel test for IgM and IgG antibodies in subjects with culture-documented genital herpes simplex virus-1 or -2 infection. *Clin Microbiol Infect* 2006;12:463-9.
90. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. *Am J Epidemiol* 2000;151:1158-71.
91. Mytton OT, McGready R, Lee SJ, Roberts CH, Ashley EA, Carrara VI, et al. Safety of benzyl benzoate lotion and permethrin in pregnancy: a retrospective matched cohort study. *BJOG* 2007;114:582-7.
92. Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the pelvic inflammatory disease evaluation and clinical health (PEACH) randomized trial. *Am J Obstet Gynecol* 2002;186:924-37.
93. Ness RB, Trautmann G, Richter HE, Randall H, Peipert JF, Nelson DB, et al. Effectiveness of treatment strategies of some women with pelvic inflammatory disease: a randomized trial. *Obstet Gynecol* 2005;106:573-80.
94. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhoea in adults in the United States. *Clin Infect Dis* 2007;44:S84-101.

95. Nieuwenhuis RF, Ossewaarde JM, Gotz HM, Dees J, Thio HB, Thomeer MG, et al. Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of *Chlamydia trachomatis* serovar I2 proctitis in the Netherlands among men who have sex with men. *Clin Infect Dis* 2004;39:996-1003.
96. O'Farrell N. Donovanosis. *Sex Transm Infect* 2002;78:452-7.
97. Odd FC. *Candida and candidosis: A Review and Bibliography*. 2nd Edn, London: Bailliere Tindall; 1988
98. Onderdonk AB, Kasper DL, Cisneros RL, Bartlett JG. The capsular polysaccharide of *Bacterioides fragilis* as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. *J Infect Dis* 1977;136:82-9.
99. Parish LC, Witkowski JA. Scabies and pediculosis. In Parish LC., Gschnait F. *Sexually Transmitted Diseases: A guide for clinicians*. New York: Springer-Verlag; 157, 1988.
100. Pedowitz P, Bloomfield RD. Ruptured adnexal abscess(tuboovarian) with generalized peritonitis. *Am J Obstet Gynecol* 1964;88:721-9.
101. Peipert JF, Boardman L, Hogan JW, Sung J, Mayer KH. Laboratory evaluation of acute upper genital tract infection. *Obstet Gynecol* 1996;87:730-6.
102. Pilcher CD, Tien HC, Eron JJ Jr., Vemazza PL, Leu SY, Stewart PW, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. *J Infect Dis* 2004;189:1785-92.
103. Pinsk I, Saloojee N, Friedlich M. Lymphogranuloma venereum as a cause of rectal stricture. *Can J Surg* 2007;50:E31-2.
104. Pitsouni E, Iavazzo C, Athanasiou S, Falagas ME. Single-dose azithromycin versus erythromycin or amoxicillin for *Chlamydia trachomatis* infection during pregnancy: a meta-analysis of randomised controlled trials. *Int J Antimicrob Agents* 2007;30:213-21.
105. Posavad CM, Wald A, Kuntz S, Suang ML, Selke S, Krantz E, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. *J Infect Dis* 2004;190:693-6.
106. Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA. Fluconazole-induced congenital anomalies in three infants. *Clin Infect Dis* 1996;22:336-40.
107. Rahangdale L, Guerry S, Bauer HM, Packel L, Rhew M, Baxter R, et al. An observational cohort study of *Chlamydia trachomatis* treatment in pregnancy. *Sex Transm Dis* 2006;33:106-110.
108. Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. *Am Fam Phys* 2005;71:933-42.
109. Read JS. Committee on Pediatric AIDS, American Academy of Pediatrics. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. *Pediatrics* 2007;120:e1547-62.
110. Reed SD, Landers DV, Sweet RL. Antibiotic treatment of tuboovarian abscess: comparison of broad-spectrum beta-lactam agent versus clindamycin-containing regimens. *Am J Obstet Gynecol* 1991;164:1556-61.
111. Reitano M, Tyring S, Lang W, Thoming C, Worm AM, Borelli S, et al. International Valaciclovir HSV Study Group. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. *J Infect Dis* 1998;178:603-10.
112. Remis RS, Gurwith MJ, Gurwith D, Hargrett-Bean NT, Lavde PM. Risk factors for urinary tract infection. *Am J Epidemiol* 1987;126:689-94.
113. Reyes M, Shaik NS, Graber JM, Nisenbaum R, Wetherall NT, Fukuda K, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. *Arch Intern Med* 2003;163:76-80.
114. Rolfs RT. Treatment of syphilis. *Clin Infect Dis* 1995;20:S23-38.
115. Romanowski B, Aoki FY, Martel AY, Lavender EA, Parsons JE, Saltzman RL. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. *AIDS* 2000;14:1211-7.
116. Rompalo AM, Joesoef MR, O'Donnell JA, Augenbraun M, Brady W, Radolf JD, et al. Clinical manifestations of early syphilis by HIV status and gender. Results of the syphilis and HIV study. *Sex Transm Dis* 1997;28:158-65.
117. Rompalo AM, Lawlor J, Seaman P, Quinn TC, Zenilman JM, Hook EW. Modification of syphilitic genital ulcer manifestations by coexistent HIV infection. *Sex Transm Dis* 2001;28:448-54.
118. Rosenthal SL, Zimet GD, Leichliter JS, Stanberry LR, Fife KH, Tu W, et al. The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. *Sex Transm Infect* 2006;82:154-7.
119. Sathia L, Ellis B, Phillip S, Winston A, Smith A. Pharyngeal gonorrhoea is dual therapy the way forward? *Int J STD AIDS* 2007;18:647-8.
120. Scott GR, Chosidow O. IUSTI/WHO. European guideline for the management of scabies, 2010. *Int J STD AIDS*. 2011;22:301-3.
121. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD Jr. Acyclovir suppression to prevent recurrent

- genital herpes at delivery. *Infect Dis Obstet Gynecol* 2002;10:71-7.
122. Sellors J, Mahony J, Goldsmith C, Rath D, Mander R, Hunter B, et al. The accuracy of clinical findings and laparoscopy in pelvic inflammatory disease. *Am J Obstet Gynecol* 1991;164:113-20.
 123. Sheffield JS, Hollier LM, Hill JB, Stuart GS, Wendel GD. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. *Obstet Gynecol* 2003;102:1396-403.
 124. Sherrard J, Donders G, White D, Jensen JS; European IUSTI, European (IUSTI/WHO) guideline on the management of vaginal discharge, 2011. *Int J STD AIDS* 2011;22:421-9.
 125. Silverberg MJ, Ahdieh L, Munoz A, Anastos K, Burk RD, Cu-Uvin S, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. *Sex Transm Dis* 2002;29:427-35.
 126. Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. *Obstet Gynecol* 2003;101:645-52.
 127. Simoes JA, Bahamondes LG, Camargo RP, Alves VM, Zaneveld LJ, Waller DP, et al. A pilot clinical trial comparing an acidbuffering formulation (ACIDFORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis. *Br J Clin Pharmacol* 2006;61:211-7.
 128. Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. *AIDS* 2006;20:741-9.
 129. Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. *Clin Infect Dis* 2001;33:1341-6.
 130. Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. *N Engl J Med* 2004;351:876-83.
 131. Sobel JD. Pathogenesis and epidemiology of vulvovaginal candidiasis. *Ann NY Acad Sci* 1988;544:547-57.
 132. Stamm WE, Counts GW, Running KR, Fihn S, Turck M, Holmes KK. Diagnosis of coliform infection in acutely dysuric women. *N Engl J Med* 1982;307:463-8.
 133. Steer R. Eradicating chancroid. *Bull World Health Organ* 2001;79:818-26.
 134. Stockfleth E, Beti H, Orasan R, Grigorian F, Mescheder A, Tawfik H, et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. *Br J Dermatol* 2008;158:1329-38.
 135. Stone KM, Reiff-Eldridge R, White AD, Cordero JF, Brown Z, Alexander ER, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984-1999. *Birth Defects Res A Clin Mol Teratol* 2004;70:201-7.
 136. Stoner BP. Current controversies in the management of adult syphilis. *Clin Infect Dis* 2007;44:S130-46.
 137. Strom BL, Collins M, West SL, Kreisberg J, Weller S. Sexual activity, contraceptive use, and other risk factors for symptomatic and asymptomatic bacteriuria: A case-control study. *Ann Intern Med* 1987;107:816-23.
 138. Sweet RL. Anaerobic- aerobic pelvic infection and pelvic abscess. In: Sweet RL, Gibbs RS, editors. *Infectious diseases of the female genital tract*, 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 189-206.
 139. Sweet RL. Pelvic inflammatory disease. In: Sweet RL, Gibbs RS, editors. *Infectious diseases of the female genital tract*, 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 368-412.
 140. Sweet RL. Role of bacterial vaginosis in pelvic inflammatory disease. *Clin Infect Dis* 1995;20:S271-5.
 141. Tapsall JW. Antibiotic resistance in *Neisseria gonorrhoeae*. *Clin Infect Dis* 2005;41:S263-8.
 142. Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. *Obstet Gynecol* 2008;111:1371-9.
 143. Timor-Tritsch IE, Lerner JP, Monteagudo A, Murphy KE, Heller DS. Transvaginal sonographic markers of tubal inflammatory disease. *Ultrasound Obstet Gynecol* 1998;12:56-66.
 144. U.S. Preventive Services Task Force. Summaries for patients. Screening for chlamydial infection: recommendations from the U.S. Preventive Services Task Force. *Ann Intern Med*. 2007.
 145. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. *Clin Infect Dis* 2002;34:944-8.
 146. Wald A, Langenberg AG, Krantz E, Douglas JM Jr, Handsfield HH, DiCarlo RP, et al. The relationship between condom use and herpes simplex virus acquisition. *Ann Intern Med* 2005;143:707-13.
 147. Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, Tyring S, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women.

- JAMA 2001;285:3100-6.
148. Wald A, Selke S, Warren T, Aoko FY, Sacks S, Diaz-Mitoma F, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. *Sex Transm Dis* 2006; 33: 529-33.
 149. Ward H, Martin I, Macdonald N. Lymphogranuloma venereum in the United Kingdom. *Clin Infect Dis* 2007;44:26-32.
 150. Washington AE, Cates W, Zadi AA. Hospitalization for pelvic inflammatory disease. Epidemiology and trends in the United States, 1975 to 1981. *JAMA* 1984;251:2529-33.
 151. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. *N Engl J Med* 2008;358:1560-71.
 152. Watts DH, Brown ZA, Money D, Selke S, Huang ML, Sacks SL, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. *Am J Obstet Gynecol* 2003;188:836-43.
 153. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. *J Infect Dis* 2005;191:1403-9.
 154. Westrom L. Incidence, prevalence and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. *Am J Obstet Gynecol* 1980;138:880-92.
 155. Wiese W, Patel SR, Patel SC, Ohl CA, Estrada CA. A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis. *Am J Med*. 2000;108:301-8.
 156. Wiesenfeld HC, Sweet RL. Progress in the management of tuboovarian abscess. *Clin Obstet Gynecol* 1993;36:433-44.
 157. Wilson JD, Shann SM, Brady SK, Mammen-Tobin AG, Evans AL, Lee RA. Recurrent bacterial vaginosis: the use of maintenance acidic vaginal gel following treatment. *Int J STD AIDS* 2005;16:736-8.
 158. Wolner-Hanssen P. Diagnosis of pelvic inflammatory disease. In: Landers DV, Sweet RL, editors. *Pelvic inflammatory disease*. New York:Springer-Verlag; 1997. p.60-75.
 159. Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep* 2010;59:1-110.
 160. Workowski KA, Berman SM. Centers for Disease Control and Prevention(CDC). Sexually transmitted diseases treatment guidelines, 2006. *MMWR Recomm Rep*. 2006;55:1-94.
 161. Yudin MH, Hilliers SL, Wiesenfeld HC, Krohn MA, Am-ortegui AA, Sweet RL. Vaginal polymorphonuclear leukocytes and bacterial vaginosis as markers for histologic endometritis among women without symptoms of pelvic inflammatory disease. *Am J Obstet Gynecol* 2003;188:318-23.
 162. Zargari O, Golchai J, Sobhani A, Dehpour AR, Sadr-Ashkevari S, Alizadeh N, Darjani A. Comparison of the efficacy of topical 1% lindane vs 5% permethrin in scabies: a randomized, double-blind study. *Indian J Dermatol Venereol Leprol* 2006;72:33-6.
 163. Zhang J, Thomas G, Leybovich E. Vaginal douching and adverse health effects. *Am J Public Health* 1997;87:1207-11.